At the news
? BEARISHIMPACT 6/10 EFFECT filed Jul 13, 2026 at 00:15 ET
Inovio Pharmaceuticals' universal shelf registration (S-3) filed July 2, 2026 has become effective, allowing the company to raise up to $300M through sales of common stock, preferred stock, debt, or warrants. This formalizes the dilution overhang flagged in the prior S-3 analysis, as the company can now take down offerings at any time. Filing document content was unavailable, analysis based on metadata and cross-filing context only.
- Shelf registration (S-3) declared effective, Inovio can now sell up to $300M in securities
- Follows S-3 filed July 2, 2026; company has a history of frequent capital raises
- Market cap is ~$97M, making potential dilution substantial relative to current equity value
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access